Skip to main content
CCSB logo

CCSB — Investor Relations & Filings

Ticker · 1762 ISIN · TW0001762003 TW Manufacturing
Open in API
Filings indexed 1,608 across all filing types
Latest filing 2020-05-12 Regulatory Filings
Country TW Taiwan
Listing TW 1762

About CCSB

www.ccsb.com.tw

Chunghwa Chemical Synthesis & Biotech Co., Ltd. (CCSB) is a specialized manufacturer of Active Pharmaceutical Ingredients (APIs) with a history dating back to 1964. The company focuses on the research, development, and large-scale production of high-quality APIs, particularly in the therapeutic areas of oncology, antifungal treatments, and immunosuppressants. CCSB offers a broad service portfolio that includes cGMP-compliant contract manufacturing and toll manufacturing. By leveraging advanced chemical synthesis and biotechnology platforms, the company provides tailored solutions to global pharmaceutical partners. CCSB adheres to rigorous international quality standards and environmental, health, and safety protocols, ensuring the reliable supply of critical medicinal components for the global healthcare market.

Recent filings

Filing Released Lang Actions
公告本公司董事會決議出售不動產
Regulatory Filings Classification · 95% confidence The document is a public announcement from a listed company (中化生) regarding a board resolution to sell real estate assets. It includes details such as the date of the board meeting, the decision to sell land, and authorization for the chairman to handle related matters. The content is about a specific corporate action (disposal of assets) decided by the board, not a full financial report or earnings release. It is not a report publication announcement or certification. This fits best under Regulatory Filings (RNS) as it is a general regulatory announcement about a corporate decision that does not fit other specific categories like MANG (management changes) or CAP (financing).
2020-05-12 Chinese
109年04月內部人持股異動(事後)
Director's Dealing Classification · 100% confidence The document consists of detailed tables listing shareholdings of insiders, including directors, managers, and their related parties, with specific numbers of shares held, increases, decreases, and other related data. The content focuses on personal share transactions and holdings by company insiders. There is no indication of financial results, management discussion, or report publication. The document is not a general regulatory announcement but specifically reports insider share transactions and holdings. Therefore, it fits the definition of Director's Dealing (DIRS). The document length is sufficient and contains substantive data, not just an announcement or certification.
2020-05-11 Chinese
109年04月董事會成員及持股
Director's Dealing Classification · 95% confidence The document is a detailed tabular disclosure of shareholdings by insiders, including directors, managers, and related parties, showing their current holdings, pledged shares, and related percentages. It is focused on insider shareholdings and does not contain financial statements, earnings data, or management discussion. It is not an announcement of a report but a direct disclosure of insider shareholdings. This matches the definition of Director's Dealing (DIRS), which covers reports of personal share transactions by company directors and executives. The document length is under 5,000 characters, but it is not merely an announcement; it contains substantive data on insider holdings. Therefore, the correct classification is DIRS with high confidence.
2020-05-11 Chinese
109年4月營業收入
Regulatory Filings Classification · 90% confidence The document is a summary report of monthly and cumulative net operating revenue figures for a company named 中化生 for the period 民國109年04月 (April 2020). It includes comparative figures from the previous year and explanations for revenue changes. The document is short (815 characters) and contains financial data but is not a full financial report like an annual or interim report. It appears to be a regulatory disclosure of financial performance data, typical of a regulatory filing or a brief financial update. There is no indication that this is a full Annual Report (10-K), Interim Report (IR), Earnings Release (ER), or other detailed report. It is more consistent with a Regulatory Filing (RNS) as it provides a regulatory disclosure of financial data without the comprehensive detail of a full report.
2020-05-08 Chinese
109年4月背書保證與資金貸與
Regulatory Filings Classification · 95% confidence The document is a brief financial disclosure from a listed company (中化生) reporting on the status of fund loans and endorsement guarantees for the current and previous month, including cumulative amounts and limits. It contains no detailed financial statements or analysis, nor does it mention any report publication or regulatory certification. The content is a regulatory disclosure of financial guarantees and loans, which does not fit into detailed financial reports like Annual or Interim Reports. Given the short length (602 characters) and the nature of the content, it is best classified as a Regulatory Filing (RNS), which serves as a general category for miscellaneous regulatory disclosures that do not fit other specific categories.
2020-05-08 Chinese
本公司負責人於臺灣高等法院108年度金上更一字第4號案宣判乙事
Legal Proceedings Report Classification · 100% confidence The document is a legal proceedings update involving the company's chairman being sentenced by a court and the company's response to the legal matter. It details the court case, the charges, and the company's statement on the impact and next steps. There is no financial data, no report attached or referenced as being published, and no indication of other filing types such as earnings, management changes, or capital updates. This fits the definition of a Legal Proceedings Report (LTR).
2020-04-30 Chinese

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.